Nuage Therapeutics focuses on discovering and developing therapeutics for oncology indications, with its lead effort directed at the SCLC-A subtype of small-cell lung cancer. The company is advancing a drug candidate designed to address the high unmet clinical need in this aggressive cancer. Its research program is being carried out in collaboration with the Spanish National Cancer Research Centre (CNIO), the European Molecular Biology Laboratory (EMBL), and the Vall d’Hebron Institute of Oncology (VHIO), providing access to top-tier scientific expertise and infrastructure. A recently awarded €2.7 million grant will finance key preclinical studies aimed at validating the drug’s mechanism of action and therapeutic potential. The non-dilutive capital strengthens Nuage Therapeutics’ balance sheet and extends its runway for R&D activities. Looking ahead, the company intends to leverage these results to position the candidate for future clinical trials and potential follow-on investment. No revenue or user metrics were disclosed in the article.

Total raised

$16M

Funding rounds

3

Latest round

Grant

Latest activity

Dec 2025